Unknown

Dataset Information

0

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.


ABSTRACT:

Background

Glioblastoma (GBM) is the most common and lethal primary malignant glioma in adults. Dendritic cell (DC) vaccines have demonstrated promising results in GBM clinical trials. However, some patients do not respond well to DC therapy, with survival rates similar to those of conventional therapy. We retrospectively analyzed clinical and laboratory data to evaluate the factors affecting vaccine treatment.

Methods

Forty-seven patients with de novo GBM were enrolled at China Medical University Hospital between 2005 and 2010 and divided into two subgroups. One subgroup of 27 patients received postsurgical adjuvant immunotherapy with autologous dendritic cell/tumor antigen vaccine (ADCTA) in conjunction with conventional treatment of concomitant chemoradiotherapy (CCRT) with temozolomide. The other 20 patients received only postsurgical conventional treatment without immunotherapy. Immunohistochemistry for CD45, CD4, CD8, programed death ligand 1 (PD-L1), and programed death 1 (PD-1) was performed on sections of surgical tumor specimens and peripheral blood mononuclear cells (PBMCs). Pearson's correlation, Cox proportional hazard model, and Kaplan-Meier analyses were performed to examine the correlations between the prognostic factors and survival rates.

Results

Younger age (<57?years), gross total resection, and CCRT and PD-1+ lymphocyte counts were significant prognostic factors of overall survival (OS) and progression-free survival (PFS) in the ADCTA group. Sex, CD45+ lymphocyte count, CD4+ or CD8+ lymphocyte count, tumor PD-L1 expression, isocitrate dehydrogenase 1 mutation, and O6 methylguanine-DNA methyltransferase promoter methylation status were not significant factors in both groups. In the ADCTA group, patients with tumor-infiltrating lymphocytes (TILs) with a lower PD-1+/CD8+ ratio (?0.21) had longer OS and PFS (median OS 60.97?months, P?P?+/CD8+ ratio (>0.21) (median OS 20.07?months, P?P?+/CD8+ ratio (?0.197) had longer OS and PFS. There was a significant correlation of PD-1+/CD8+ ratio between TILs and PBMCs (Pearson's correlation R2?=?0.6002, P?-, CD8-, but PD-1+, CD45+ tumor-infiltrating lymphocytes have no impact on OS and PFS (P?=?0.073 and P?=?0.249, respectively).

Conclusion

For patients receiving DC vaccine adjuvant therapy, better outcomes are predicted in patients with younger age, with TILs or PBMCs with lower PD-1+/CD8+ ratio, with gross tumor resection, and receiving CCRT.

SUBMITTER: Jan CI 

PROVIDER: S-EPMC5992384 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.

Jan Chia-Ing CI   Tsai Wan-Chen WC   Harn Horng-Jyh HJ   Shyu Woei-Cherng WC   Liu Ming-Chao MC   Lu Hsin-Man HM   Chiu Shao-Chih SC   Cho Der-Yang DY  

Frontiers in immunology 20180529


<h4>Background</h4>Glioblastoma (GBM) is the most common and lethal primary malignant glioma in adults. Dendritic cell (DC) vaccines have demonstrated promising results in GBM clinical trials. However, some patients do not respond well to DC therapy, with survival rates similar to those of conventional therapy. We retrospectively analyzed clinical and laboratory data to evaluate the factors affecting vaccine treatment.<h4>Methods</h4>Forty-seven patients with <i>de novo</i> GBM were enrolled at  ...[more]

Similar Datasets

| S-EPMC6216147 | biostudies-literature
2009-04-03 | GSE11100 | GEO
| S-EPMC10493805 | biostudies-literature
| S-EPMC4022230 | biostudies-literature
| S-EPMC6403044 | biostudies-literature
| S-EPMC4849730 | biostudies-literature
| S-EPMC7592424 | biostudies-literature
| S-EPMC8335808 | biostudies-literature
| S-EPMC8895466 | biostudies-literature
| S-EPMC7071600 | biostudies-literature